Skip to main content

Pipeline

Aelin Therapeutics’ platform fuels a transformative therapeutics pipeline

Our current pipeline: oncology and infectious disease

Aelin Therapeutics is currently advancing programs to candidate selection and early-stage clinical research. We have demonstrated strong proof-of-concept in oncology and infectious disease with two Pept-in compounds progressing to preclinical lead nomination with compelling baseline in vitro data and in vivo pharmacology. We continue to generate new candidates with our proprietary in silico design platform, Athena, for the functional knock-down of mammalian, bacterial, viral and fungal proteins for the treatment of human diseases.

Click on diagram to view fullscreen

Reaching undruggable cancer targets

Only 20% of cell proteins can be targeted by conventional therapeutic approaches, with many tumor proteins remaining “undruggable”. Protein degradation has long been viewed as an approach to solve this issue and inhibit key oncoproteins. Aelin Therapeutics is offering a new and powerful approach by harnessing an innate regulatory mechanism: inducing aggregation and misfolding, or preventing the correct folding of target oncoproteins. Aelin’s approach is complimentary to existing cancer therapies and creates a new breadth of therapeutic potential.

Preclinical data of our cancer-targeting Pept-ins demonstrate:

  • Pept-ins enter the cell
  • Pept-ins bind to the oncology protein target (KRAS) in a selective manner
  • Pept-ins induce aggregation of the target protein (KRAS) followed by cell death
  • KRAS Pept-in reduces tumor burden in vivo to the same extent as Trametinib, in KRAS mutant-driven allograft model
Cancer targets
Antimicrobial innovation

Meeting the need for antimicrobial innovation

Increasing numbers of bacteria are becoming resistant to antibiotics, escalating the number of patients dying from untreatable infections. In particular, Gram-negative bacteria are a major cause for illness and death around the world.

Pept-ins present a promising and novel solution to antimicrobial resistance. While most APRs are unique, a small minority allows for redundancy in multiple proteins or across multiple pathogens. Aelin Therapeutics has designed Pept-ins to target such cross-reactive APRs in the bacterial proteome, leading to a selective proteostatic collapse of the bacteria with no toxicity to human host’s cells while inducing death (cidality) of the targeted bacteria. This clears even multi-drug resistant (MDR) infections quickly and efficiently.

Preclinical data of our antimicrobial Pept-ins demonstrate:

  • 5 WHO criteria met: new mode of action, new chemistry, new targets, fast killing, no cross-resistance to other antibiotic classes
  • Pept-ins kill bacteria rather than suppressing growth
  • They have a broad activity spectrum, targeting multiple bacterial species with one Pept-in
  • Activity is not influenced by the current MDR genotype or phenotype
  • Resistance develops very slow, if at all, thanks to the fast kinetics of killing and its effect on multiple proteins creating a larger hurdle for corrective mutations
  • Effectiveness against 150 WHO-listed pathogens and clinical isolates (including isolates with existing resistance to current treatments)

Would you like more information on our Pept-in technology?

Send us a message